Cambodia | Malaysia | Mongolia | |
---|---|---|---|
Date of data collection | Feb – Apr 2010 | Sep 2005 – Feb 2006 | Oct-Dec 2009 |
Response rate | |||
Questionnaire | 96.3% | 84.6% | 95% |
Physical measurements | 94.2% | 84.6% | 95% |
Biochemical measurements | 92.7% | 84.6% | 95%1 |
Sample size aged (25–64) | 5,433 | 2,572 | 4,539 |
Sample size aged (40–64 years) | 3244 | 1631 | 2234 |
Sample size aged 40–64 years with data on DM & HT & included in the current study for CVD risk assessment | 3090 | 1618 | 8451 |
Male: % | 35.0 | 42.3 | 40.5 |
Unweighted (N) | (1137) | (690) | (905) |
Weighted (%) | 47.4 | 51.3 | 50.3 |
Age in years: mean (SD) | |||
Unweighted | 49.7 (0.15) | 50.3 (0.17) | 49.2 (0.14) |
Weighted | 50.7 (0.12) | 49.2 (0.71) | 48.9(0.16) |
Measurement of Blood pressure (measured 3 times in sitting position) | NISSEI Digital Blood Pressure Monitor (Model DS-500) | Stethoscope & mercury-stand sphygmomanometer | Omron Model 5 Automatic Blood Pressure Monitor |
Measurement of fasting Blood/plasma sugar and cholesterol | Whole capillary blood taken from fingertips; dry chemical reagent strips & Accutrend GCT instruments | 5 ml venous blood; plasma glucose: enzymatic assay kit (GlucoseFlex® reagent cartridge); total cholesterol: enzymatic colorimetric tests | Same as in Cambodia |